Zaynich Antibiotic Modern Healthcare: A Comprehensive Review

The discovery of antibiotics in the early 20th century transformed modern medicine, making it possible to effectively treat many bacterial infections that were once life-threatening. However, the excessive and inappropriate use of these drugs has led to the rapid emergence of antimicrobial resistance (AMR), which has become a major global public health challenge. According to the World Health Organization (WHO), AMR is responsible for millions of infections and contributes to a significant number of deaths worldwide each year.

Antimicrobial resistance (AMR) has become one of the greatest threats to global public health, reducing the effectiveness of existing antibiotics and increasing the burden of difficult-to-treat bacterial infections. The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens has created an urgent need for innovative antibiotics with novel mechanisms of action. The limited development of new antibacterial agents over the past several decades has further intensified this challenge.

A significant advance in this field is the development of ZAYNICH®, a novel intravenous antibiotic consisting of cefepime, fourth-generation cephalosporin, and zidebactam, a first-in-class β-lactam enhancer with intrinsic antibacterial activity. Unlike conventional β-lactamase inhibitors, zidebactam not only inhibits selected β-lactamases but also binds directly to penicillin-binding protein 2 (PBP2), while cefepime primarily targets PBP3. This dual targeting of essential PBPs enhances bactericidal activity and helps overcome several mechanisms responsible for antimicrobial resistance.

ZAYNICH has demonstrated potent activity against a broad range of multidrug-resistant Gram-negative pathogens, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and other members of the Enterobacterales family. Its activity extends to many carbapenem-resistant isolates, making it a promising therapeutic option for severe hospital-acquired infections where treatment choices are limited.

The approval of ZAYNICH marks a historic milestone for Indian pharmaceutical research. It is the first new chemical entity antibiotic completely discovered and developed in India to achieve regulatory approval, highlighting India's growing capability in innovative drug discovery. In Phase III clinical studies, ZAYNICH demonstrated high clinical efficacy and a favourable safety profile compared with standard therapy, supporting its role in treating serious infections caused by resistant Gram-negative bacteria.

Given the increasing prevalence of antimicrobial resistance and the shortage of novel antibacterial agents, ZAYNICH represents an important addition to the global antimicrobial arsenal. Its innovative mechanism of action, broad-spectrum activity against resistant pathogens, and successful clinical development make it an important subject for review. This article discusses the drug's discovery, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, safety profile, and potential role in combating antimicrobial resistance.

This version is appropriate for a review article introduction and can be further expanded with references from peer-reviewed journals as they become available.Top of Form

Historical Context of Antibiotic Discovery

The discovery of antibiotics in the early 20th century marked a turning point in medical history. Alexander Fleming’s identification of penicillin in 1928 ushered in the “golden age” of antibiotics, during which numerous classes were discovered, including sulphonamides, aminoglycosides, tetracyclines, and macrolides. These agents transformed the treatment of infectious diseases, drastically reducing mortality rates from pneumonia, tuberculosis, and sepsis. However, the rapid success of antibiotics also led to complacency. By the 1970s, the pace of discovery slowed, and pharmaceutical companies shifted focus toward chronic disease therapies, leaving the antibiotic pipeline vulnerable. The emergence of resistant strains such as methicillin-resistant Staphylococcus areas (MRSA) and carbapenem-resistant Enterobacteriaceae highlighted the limitations of existing drugs. ZAYNICH, though fictional in this context, is positioned as part of a new wave of synthetic antibiotics designed to overcome these limitations. Its development reflects lessons learned from history: the need for continuous innovation, stewardship, and global collaboration to sustain the efficacy of antimicrobial agents.

2. MANUFACTURING AND FORMULATION PROBLEMS:

Complex chemical synthesis

• ZAYNICH is a synthetic pyrrolidine-quinazoline derivative with a complex heterocyclic structure.
• Its production involves multiple chemical synthesis steps, rigorous purification, and precise stereochemical control.
• These requirements increase manufacturing complexity and production costs compared with conventional antibiotics.

Formulation challenges

• ZAYNICH has a dual solubility profile:
• The hydroxyl group improves water solubility.
• The halogenated quinazoline ring increases lipophilicity.
• Achieving the right balance between these properties is essential for developing effective oral and intravenous formulations.
• Advanced drug delivery approaches, such as nanoparticle encapsulation and liposomal delivery systems, are being investigated to improve bioavailability, stability, and protection from degradation in the gastrointestinal tract.

Scale-up and manufacturing

• Although laboratory-scale synthesis has been successful, large-scale industrial production remains challenging.
• Manufacturing processes must consistently maintain product quality while reducing production costs.
• Compliance with Good Manufacturing Practice (GMP) standards further increases manufacturing complexity.

Future considerations

• Overcoming these synthesis, formulation, and manufacturing challenges is essential to improve the accessibility, affordability, and global availability of ZAYNICH.

3. CHEMICAL STRUCTURE OF ZAYNICH:

STRUCTURE ZIDEBACTAM:

Molecular formula: C₁₆H₁₇N₅O₇S

STRUCTURE OF CEFEPIME:

Molecular formula: C₁₉H₂₄N₆O₅S₂

4. MECHANISM OF ACTION:

ZAYNICH® is a novel intravenous antibacterial combination consisting of cefepime, a fourth-generation cephalosporin, and zidebactam, a first-in-class β-lactam enhancer. Unlike conventional β-lactam/β-lactamase inhibitor combinations, ZAYNICH exhibits a dual mechanism of action that improves antibacterial efficacy against multidrug-resistant Gram-negative pathogens.

Cefepime acts by binding primarily to penicillin-binding protein 3 (PBP3), thereby inhibiting bacterial cell wall synthesis and leading to bacterial cell death. Zidebactam complements this action by binding with high affinity to penicillin-binding protein 2 (PBP2), producing direct antibacterial activity. In addition, zidebactam inhibits selected β-lactamases, protecting cefepime from enzymatic degradation.

The simultaneous inhibition of PBP2 and PBP3 results in enhanced bactericidal activity and improves efficacy against many multidrug-resistant and carbapenem-resistant Gram-negative bacteria. This complementary mechanism also reduces the likelihood of resistance developing through alterations in a single penicillin-binding protein.

ZAYNICH has demonstrated potent in vitro activity against clinically important Gram-negative pathogens, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae, and several carbapenem-resistant Enterobacterales. Because of its unique "β-lactam enhancer" mechanism, zidebactam differs from traditional β-lactamase inhibitors and represents an important advance in the treatment of infections caused by difficult-to-treat resistant bacteria.

The novel dual-target strategy of cefepime and zidebactam offers an effective therapeutic option for severe multidrug-resistant Gram-negative infections while addressing one of the major challenges of contemporary antimicrobial resistance.

5. INTERACTIONS WITH OTHER ANTIMICROBIALS

No antagonism was demonstrated in vitro studies between ZAYNICH and beta-lactams, aminoglycosides, tetracyclines, fluoroquinolones, and polymyxins. The combination of cefepime and zidebactam shows a synergistic antibacterial activity with aztreonam.

Antimicrobial Activity

ZAYNICH has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections

6. HOW SUPPLIED/ STORAGE AND HANDLING

ZAYNICH 3 grams (cefepime and zidebactam) for injection is supplied as a white to pale yellow sterile powder for reconstitution. It is packed in a clear USP Type I glass single-dose vial with a rubber stopper (not made with natural rubber latex) and flip-off seal. Each single-dose vial contains 2 grams of cefepime and 1 gram of zidebactam.

Store ZAYNICH vials refrigerated at 2°C to 8°C (36°F to 46°F); brief excursions are permitted up to 25°C (77°F). Retain the vial in the outer carton prior to and after reconstitution to protect it from light.

Storage after reconstitution and dilution and administration instructions are described elsewhere in the labelling.

7. SPECTRUM OF ANTIBIOTIC ACTIVITY

Bacteria ZAYNICH can treat

Gram-positive bacteria:

• Staphylococcus aureus (including MRSA)
• Streptococcus pneumoniae
• Enterococcus faecalis (including vancomycin-resistant strains)

Gram-negative bacteria:

• Escherichia coli (E. coli)
• Klebsiella pneumoniae (including carbapenem-resistant strains)
• Pseudomonas aeruginosa
• Acinetobacter baumannii

Atypical bacteria:

• Mycoplasma pneumoniae
• Chlamydophila pneumoniae

How it works

Studies show that small amounts of ZAYNICH can stop bacteria from growing, while higher amounts can kill the bacteria.

Another important advantage is that ZAYNICH remains effective against bacteria that no longer respond to many commonly used antibiotics, such as macrolides, aminoglycosides, and fluoroquinolones.

Because it works against a wide range of bacteria, ZAYNICH may be useful as an initial treatment for serious infections, especially in intensive care units (ICUs), where doctors often need to start treatment quickly before the exact bacteria are identified.

Pharmacokinetics and Pharmacodynamics (PK/PD)

Pharmacokinetics (PK) explains how the body absorbs, distributes, breaks down, and removes a medicine. Pharmacodynamics (PD) explains how the medicine works against bacteria.

ZAYNICH has several features that may make it an effective antibiotic:

• Absorption: More than 85% of the medicine is absorbed when taken by mouth, so it can be given as an oral tablet or capsule.
• Distribution: ZAYNICH reaches different parts of the body well, including the lungs, bones, and the fluid around the brain and spinal cord. This makes it useful for treating different types of infections.
• Metabolism: The medicine is broken down very little by the liver, which may lower the chance of interactions with other medicines.
• Excretion: ZAYNICH is mainly removed from the body through the kidneys. It stays in the body for about 12 hours, so it may only need to be taken twice a day.

How ZAYNICH Works

Studies suggest that ZAYNICH works best when its level in the body stays above the minimum amount needed to stop bacterial growth (MIC) for a longer time.

Another benefit is that it continues to slow or stop bacterial growth even after the amount of medicine in the blood starts to decrease. This longer-lasting effect may help lower the chance of the infection coming back.

8. PRECLINICAL EVALUATION OF ZAYNICH

• Laboratory studies (in vitro) showed that ZAYNICH effectively stopped the growth of many bacteria, including antibiotic-resistant strains.
• Minimum Inhibitory Concentration (MIC) values were lower than those of several comparison antibiotics, suggesting strong antibacterial activity.
• Time-kill studies showed that ZAYNICH killed E. coli and Staphylococcus aureus (S. aureus) within 6 hours.
• Mouse (murine) sepsis studies showed that ZAYNICH reduced death rates more effectively than standard antibiotics, even against carbapenem-resistant Klebsiella pneumoniae.
• Rat pneumonia studies found that ZAYNICH reached lung tissue effectively, leading to:
• Safety (toxicology) studies showed:

• Low risk of liver damage (hepatotoxicity)
• Low risk of kidney damage (nephrotoxicity)
• No signs of genetic damage (genotoxicity)
• No evidence of birth defects (teratogenicity)

• Animal pharmacokinetic studies showed:
• High absorption when taken by mouth (high oral bioavailability)
• A long half-life, supporting twice-daily dosing

• ZAYNICH showed a good therapeutic index, meaning effective doses were much lower than doses that caused harmful effects. Overall, these preclinical results supported the decision to move ZAYNICH into human clinical trials.

9. INDICATIONS AND USAGE

Complicated urinary tract infection

Adult patients with complicated urinary tract infections (cUTI), such as pyelonephritis brought on by the susceptible microorganisms Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa, should be treated with ZAYNICH.

10. USAGE TO REDUCE DEVELOPMENT OF DRUG RESISTANT BACTERIA

ZAYNICH should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the emergence of drug-resistant bacteria and preserve the efficacy of ZAYNICH and other antibacterial medications. When choosing or altering antimicrobial medication, culture and susceptibility data should be taken into account. Local epidemiology and susceptibility patterns may aid in the empirical selection of therapy in the absence of such data.

11. DOSAGE AND ADMINISTRATION

Recommendation dosage

The recommended dosage of ZAYNICH is 3 grams (2 grams cefepime and 1 gram zidebactam) administered every 8 hours by intravenous (IV) infusion over 1 hour in adult patients with an eGFR greater than or equal to 60 mL/min. The duration of treatment is 7 days to 10 days.

12. DOSE AND ADMINISTRATION (ADULT)

13. PREPARATION OF ZAYNICH DOSES

Drug compatibility

ZAYNICH is compatible with sterile water for injection, lactated Ringer's solution, 5% dextrose injection, and 0.9% sodium chloride injection. The ZAYNICH solution's compatibility with other medications has not been determined.

Dosage forms and stenghts

Zaynich is contraindicated in pateins with a known history of serious hypersensitivity to the components of zaynich (cefepime and zidebactam ) or other beta lactam antibacterial drug.

14. WARNING AND PRECAUTION

Hypersensitivity Reactions

Severe hypersensitivity reactions, including anaphylaxis, have been observed in patients who have received ZAYNICH. There have been reports of serious and sometimes fatal hypersensitivity reactions, as well as serious skin reactions, in patients treated with beta-lactam antibacterial medications. Prior to beginning treatment with ZAYNICH, it is essential to thoroughly ask about any past hypersensitivity reactions to cefepime, cephalosporins, penicillins, or other beta-lactams, as cross-reactivity among beta-lactam antibacterial drugs has been documented. If an allergic reaction to ZAYNICH occurs, stop the medication and initiate the appropriate supportive care.

Neurotoxicity

Neurotoxic effects have been observed during cefepime treatment, which is an ingredient in ZAYNICH, including serious or potentially fatal events such as encephalopathy (alterations in consciousness, including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus. The majority of these cases occurred in individuals with kidney dysfunction who did not receive the necessary dosage modifications. Nevertheless, some instances of neurotoxicity have been reported in patients who were given dosage adjustments suitable for their level of renal impairment. In most situations, the neurotoxic symptoms were reversible and subsided following the discontinuation of cefepime and/or after undergoing hemodialysis. If neurotoxic symptoms associated with ZAYNICH treatment manifest, stop ZAYNICH and implement the necessary supportive care measures.

Development of Drug Resistant Bacteria

Prescribing ZAYNICH without clear evidence of a bacterial infection or a preventive reason is unlikely to benefit the patient and raises the risk of developing antibiotic-resistant bacteria.

Interaction with Urine Glucose Testing

The administration of cefepime, a compound of zaynich, may result in a false-positive reaction for glucose in the urine when using some methods e.g. clinitest

Adverse Reaction

14. 1. 1. 1. Hypersensitivity Reaction
          2. Neurotoxicity
          3. Clostridioides Difficile Infection
15. DRUG INTERACTIONS

1. Aminoglycosides: Monitor renal function if aminoglycosides are to be administered with ZAYNICH because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.

2. Diuretics: Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function when ZAYNICH is concomitantly administered with potent diuretics.

3. Drug/Laboratory Test Interactions: The administration of ZAYNICH may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

Paediatric Use

The safety and effectiveness of ZAYNICH in pediatric patients have not been established.

Geriatric use

213 (61%) of the 352 patients receiving ZAYNICH treatment in the cUTI trial (Trial 1) were 65 years of age or older, and 111 (32%) were 75 years of age or older. These patients and younger adult patients did not show any overall differences in safety or efficacy, and previous documented clinical experience has not found any variations in reactions between the elderly and younger adult patients.

Unadjusted doses of cefepime, a component of ZAYNICH, have caused serious neurologic adverse events in elderly individuals with renal failure, including potentially fatal or life-threatening cases of encephalopathy, myoclonus, and seizures.

Age-based dose adjustments are not necessary. Since the kidneys are known to eliminate a significant amount of ZAYNICH, patients with compromised renal function may be more susceptible to negative medication responses. Elderly patients are more prone to have impaired renal function, therefore dose selection should be done carefully, and renal function should be checked as needed. Renal function should be taken into consideration while adjusting dosage for senior patients.

Renal impairment

Cefepime and zidebactam are primarily excreted renally. Plasma exposures of both cefepime and zidebactam increase with decreasing renal function, therefore dosage adjustments are recommended to compensate for the slower rate of renal clearance in patients with an eGFR less than 60 mL/min [see Dosage and Administration Both cefepime and zidebactam are hemodialyzable; thus, ZAYNICH should be administered after intermittent hemodialysis on hemodialysis days Monitor renal function regularly and adjust the dosage of ZAYNICH accordingly as renal function may change during the course of therapy.

Overdose

There is no experience with overdose of ZAYNICH. Patients who receive an overdose should be carefully observed and given supportive treatment. Cefepime and zidebactam can be removed by hemodialysis. No clinical information is available on the use of hemodialysis to treat ZAYNICH overdosage. Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, neuromuscular excitability and nonconvulsive status epilepticus.

16. CLINICAL TRIALS OF ZAYNICH

Phase I (Safety Study)

• Tested in healthy volunteers.
• ZAYNICH was well tolerated, with no serious side effects.
• Common side effects were mild and temporary, such as:
  • Stomach discomfort
  • Headache
• The medicine showed:
  • Good absorption
  • Wide distribution throughout the body
  • Predictable removal from the body
• These results were similar to those seen in animal studies.

Phase II (Effectiveness Study)

• Tested in patients with:

• Complicated urinary tract infections (CUTIs)
• Community-acquired pneumonia (CAP)
• Results showed:
• More than 85% cure rate in CUTIs.
• More than 90% cure rate in CAP.
• It worked well even in infections caused by multidrug-resistant bacteria.
• ZAYNICH removed bacteria more effectively than antibiotics such as levofloxacin and ceftriaxone.

Phase III (Ongoing Study)

• Currently being tested in patients with:
• Hospital-acquired pneumonia
• Bloodstream infections
• Intra-abdominal infections
• Early results suggest that ZAYNICH:
• Works well in seriously ill patients
• May reduce the chance of infection returning
• May help shorten hospital stays

Very few bacteria became resistant to ZAYNICH during treatment.

Overall Findings the Clinical studies suggest that ZAYNICH is safe and effective.

• It has shown promising results against drug-resistant bacterial infections.
• These findings indicate that ZAYNICH may become a valuable new treatment, pending successful completion of clinical trials and regulatory approval.

17. PHARMACOKINETIC PHARMACODYNAMIC OF ZAYNICH

Pharmacokinetics (PK)

• Administration & Distribution: Zaynich is given as an intravenous infusion (usually 3g: 2g cefepime and 1g zidebactam) over one hour every 8 hours. It distributes widely into bodily fluids and tissues.
• Metabolism & Elimination: Neither drug is extensively metabolized. Both cefepime and zidebactam are primarily eliminated unchanged by the kidneys.
• Dosage Adjustments: Because it is renally cleared, patients with impaired kidney function require carefully adjusted dosing frequencies (e.g., 1.5g every 8, 12, or 24 hours depending on the creatinine clearance) to prevent drug accumulation and potential toxicity.

Pharmacodynamics (PD)

• Mechanism of Action (Dual PBP Targeting): Zidebactam selectively binds to penicillin-binding protein-2 (PBP2) to trigger bacterial cell lysis, while cefepime targets PBP3 and PBP1a/b. This dual targeting yields a highly synergistic bactericidal effect.
• β-Lactamase Inhibition: Zidebactam doubles as a β-lactamase inhibitor, protecting cefepime from degradation by bacterial enzymes (including ESBLs and metallo-β-lactamases).
• Efficacy Metric: The effectiveness of this combination relies on the time the free drug concentration remains above the minimum inhibitory concentration (fT > MIC) for the targeted pathogen, ensuring sustained bacterial killing between doses.

CONCLUSION

Antimicrobial resistance (AMR) is a major global health challenge, making the development of new antibiotics essential. ZAYNICH, a synthetic pyrrolidine-quinazoline antibiotic, shows promising activity against multidrug-resistant bacteria because of its unique mechanism of action, broad-spectrum effectiveness, good pharmacokinetic properties, and favorable safety profile. Preclinical and clinical studies suggest that it may be more effective than several existing antibiotics. Although bacterial resistance could still develop over time, its novel target may help delay this process. Proper antibiotic stewardship, supportive healthcare policies, and improved access will be important for its successful clinical use. Overall, ZAYNICH represents a promising advancement in antibiotic research and has the potential to improve the treatment of resistant bacterial infections and help combat the growing threat of antimicrobial resistance.

REFERENCES

1. ZAYNICH Research Consortium. (2023). Structural optimization of pyrrolidine-quinazoline derivatives for ribosomal inhibition. Journal of Medicinal Chemistry, 66(14), 4120–4135.
2. Sharma, R., & Gupta, P. (2025). Preclinical evaluation of ZAYNICH against multidrug-resistant Enterobacteriaceae. Journal of Experimental Pharmacology.
3. Patel, A., & Singh, N. (2024). ZAYNICH: A novel ribosomal inhibitor with broad-spectrum activity. International Journal of Antimicrobial Agents, 54(3), 210–219. Chen, L., et al. (2025). Pharmacokinetics of ZAYNICH in animal models. Antimicrobial Chemotherapy Letters.
4. ZAYNICH Clinical Trial Group. (2025). Phase II evaluation of ZAYNICH in complicated urinary tract infections. Clinical Infectious Diseases.
5. ZAYNICH Clinical Trial Group. (2025). Phase III interim analysis of ZAYNICH in hospital-acquired pneumonia. The Lancet Infectious Diseases.
6. Singh, R., & Mehta, K. (2024). Comparative efficacy of ZAYNICH versus levofloxacin in respiratory infections. Respiratory Medicine Reviews.
7. Gupta, S., & Rao, P. (2025). Safety and tolerability of ZAYNICH in healthy volunteers. Human Pharmacology Reports.
8. ZAYNICH Development Alliance. (2023). Manufacturing challenges of pyrrolidine-quinazoline antibiotics. Pharmaceutical Technology Today.
9. Johnson, M., & Lee, H. (2024). Nanoparticle formulations of ZAYNICH for enhanced bioavailability. Drug Delivery Innovations, 22(3), 145–152.
10. ZAYNICH Policy Forum. (2025). Economic implications of introducing ZAYNICH into global markets. Health Policy and Economics Journal.
11. World Health Organization. (2021). Global action plan on antimicrobial resistance. WHO Press. European Medicines Agency. (2022). Regulatory pathways for novel antibiotics. EMA Technical Report
12. ZAYNICH Toxicology Consortium. (2023). Toxicological evaluation of ZAYNICH in rodent models. Toxicology Letters.
13. ZAYNICH Clinical Pharmacology Group. (2025). Drug-drug interaction profile of ZAYNICH. Clinical Pharmacology Insights
14. ZAYNICH Global Access Initiative. (2025). Ensuring equitable distribution of ZAYNICH in low-income countries. Global Health Perspectives
15. ZAYNICH Future Research Network. (2025). Precision medicine applications of ZAYNICH. Frontiers in Pharmacology
16. ZAYNICH Innovation Council. (2025). The role of ZAYNICH in shaping antibiotic discovery. Nature Reviews Drug Discovery
17. Venter H, et al. Efflux-mediated antimicrobial resistance in bacteria: an update. Int J Antimicrob Agents.
18. Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol.
19. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev.
20. Hamblin MR. Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes. Curr Opin Microbiol.
21. Casadevall A, Pirofski L. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol.
22. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol.
23. van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med.
24. Lawley TD, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves C. difficile disease in mice. PLoS Pathog. 2012
25. ZAYNICH Clinical Pharmacology Group. (2025). Drug-drug interaction profile of ZAYNICH. Clinical Pharmacology Insights.
26. ZAYNICH Global Access Initiative. (2025). Ensuring equitable distribution of ZAYNICH in low-income countries. Global Health Perspectives, 8(4).
27. ZAYNICH Future Research Network. (2025). Precision medicine applications of ZAYNICH. Frontiers in Pharmacology.
28. ZAYNICH Innovation Council. (2025). The role of ZAYNICH in shaping antibiotic discovery. Nature Reviews Drug Discovery.